San Diego-dependent Viking Therapeutics marked itself as a serious competitor from the weight loss drug market place in February soon after revealing promising information from a mid-stage trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when offered like a weekly injection As well as in March